UNSPSC 51123502: Zatebradine

This classification denotes an antiarrhythmic agent with the molecular formula C26H36N2O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) TV27RY5876, chemically known as 3-(3-((3,4-dimethoxyphenethyl)methylamino)propyl)-1,3,4,5-tetrahydro-7,8-dimethoxy-2h-3-benzazepin-2-one but more generally known as zatebradine, which bears US NIH Compound Identifier 65637. European Medicines Agency schedules Zatebradine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00143MIG.

UNSPSC 51123502 Zatebradine, a Commodity code, covers pharmaceutical products procured by state and local governments for emergency medical services, public health programs, and cooperative purchasing networks. State and local buyers under this code are acquiring advanced life support medications, generic pharmaceuticals, and over-the-counter products for distribution through authorized wholesalers and direct delivery to end users such as fire rescue departments and state health agencies. Issuing bodies include municipal fire departments (Tampa Fire Rescue), state health and human services commissions (Texas HHS Commission), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP). The solicitation mix spans both transactional commodity buys—sealed bids for specific medication line items with firm pricing and rapid delivery—and strategic procurement vehicles such as cooperative purchasing frameworks and exploratory RFIs designed to establish long-term vendor relationships and direct-to-manufacturer contracting pathways.

Recent activity clusters in Florida and the Upper Midwest, with Texas playing a secondary strategic role. The City of Tampa's Purchasing Department posted a sealed bid (IFB 26P00188) in April 2026 for advanced life support medications including Labetalol HCI, Epinephrine, Adenosine, and Diltiazem vials, with a due date of April 8, 2026 and an estimated contract value of $40,000.00, featuring a 5 percent SLBE bid discount capped at $10,000. MMCAP, administered by the Minnesota Department of Administration, issued an RFP (S1070000015802) in January 2026 for generic multi-source pharmaceuticals and OTC products across participating state and local facilities in Minnesota and Oregon, with proposals due March 26, 2026 and contract effectiveness July 1, 2026; the RFP weights price competitiveness at 75 percent and requires vendors to maintain relationships with three authorized wholesalers. The Texas Health and Human Services Commission issued an exploratory RFI (HHS0017013) in March 2026 to gather vendor capabilities for a direct-to-manufacturer prescription program, signaling future formal procurement interest in novel contracting models outside traditional PBM and GPO channels.